REFERENCES
Gaggi R, Gianni AM (1973) The role of homocysteine in the pathogenesis of arteriosclerosis. Proc First Cong Hung Pharmacol Soc 2: 287–297.
Gibson JB, Carson NAJ, Neill DW (1964) Pathological findings in homocystinuria. J Clin Pathol 17: 427–437.
Harpel PC, Chang VT, Borth W (1992) Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89: 10193–10197.
McCully KS, Olszewksi AJ, Vezeridis MP (1990) Homocysteine and lipid metabolism in atherogenesis: effect of the homocysteine thiolactonyl derivatives, thioretinaco and thioretinamide. Atherosclerosis 83: 197–206.
Mudd SH, Skovby F, Levy HL, et al (1985). The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am J Hum Genet 37: 1–31.
Rader DJ, Ikewalei K (1996) Unravelling high density lipoproteins-apoliprotein metabolism in human mutants and animal models. Curr Opin Lipidol 7: 117–123.
Spaapen LJM, Waterval WAH, Bakker JA, et al (1992) Detectie van hyperhomocysteinemie bij cerebrovasculaire ziekte. Tijdschr NV KC 17: 194–199.
Wilcken DEL, Wilcken B (1997) The natural history of vascular disease in homocystinuria and the e.ects of treatment. J Inher Metab Dis 20: 295–300.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moat, S.J., Bonham, J.R., Allen, J.C. et al. Decreased circulating plasma lipids in patients with homocystinuria. J Inherit Metab Dis 22, 243–246 (1999). https://doi.org/10.1023/A:1005565518228
Issue Date:
DOI: https://doi.org/10.1023/A:1005565518228